Hypoparathyroidism Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Hypoparathyroidism Market Size - Analysis

Hypoparathyroidism Market Trends

The number of hypoparathyroidism cases has been rising steadily over the past decade, primarily driven by the increasing incidence of thyroid surgeries as well as a sharp rise in autoimmune disorders that can potentially lead to underactive parathyroid glands.

Furthermore, advancements in diagnostic techniques have enabled more reliable identification of hypoparathyroidism cases that may previously have gone undiagnosed or misdiagnosed. Combined with the general population growth globally, these determining factors have widened the patient pool suffering from inadequate or no parathyroid hormone production.

A successful parathyroid hormone replacement regimen is pivotal to mitigating complications arising from long-term hypoparathyroidism such as hypocalcemia. Traditionally, supplements containing calcium carbonate and vitamin D derivatives were relied upon to artificially boost calcium levels. However, relying solely on these approaches often fell short of comprehensively addressing the multifaceted hormonal deficiencies associated with hypoparathyroidism. The last decade has thus witnessed encouraging progress on the drug development front, including approvals of the first recombinant parathyroid hormone therapies.

Compared to conventional treatments, recombinant drugs enable more physiologic restoration of hormone signaling pathways deficient in hypoparathyroidism patients.

Market Challenge - Expensive Therapies Limiting Patient Access, Especially in Developing Regions

For many patients in lower-income countries, gaining regular access to prescription medications is simply not financially feasible. Even in regions with some form of universal healthcare, the high drug prices may mean hypoparathyroidism treatments are not widely reimbursed.

Unless more affordable treatment options emerge, a large proportion of hypoparathyroidism sufferers globally will remain without proper care.

Market Opportunity - Growing Healthcare Infrastructure Presents New Market Opportunities

Where public hospitals and clinics have previously lacked resources to identify rare diseases, improving facilities and trained staff open new avenues for hypoparathyroidism screening, diagnosis and long-term support. A developing middle-class also increases the percentage of people with insurance or the means to regularly purchase medications.

Prescribers preferences of Hypoparathyroidism Market

Hypoparathyroidism is typically treated via a stepwise approach based on the severity of symptoms. For mild cases with only periodic symptoms, prescribers may first recommend oral calcium and vitamin D supplements like Tocomin and Caltrate. These aim to maintain appropriate calcium levels and prevent long term complications.

In refractory cases where the above options provide insufficient control, surgical parathyroid gland implantation is explored. This aims to permanently restore endogenous PTH production. Post-surgery, lifelong supplemental activated vitamin D and calcium are still required in most cases. Brands like Rocaltrol and OsCal are commonly prescribed long-term for maintenance.

Treatment Option Analysis of Hypoparathyroidism Market

Hypoparathyroidism treatment depends on the severity and stage of the condition. Mild cases are often treated with calcium and vitamin D supplements. However, more severe long-term cases may require additional therapies.

For stage 3-4 patients, oral calcitriol (Rocaltrol) or injectable parathyroid hormone drugs like teriparatide (Forteo) are prescribed. Calcitriol promotes calcium absorption from food while replenishing vitamin D levels. It is preferred first due to its low cost. However, it provides less reliable control than parathyroid hormone therapies. Forteo is a recombinant form of PTH that more effectively regulates calcium and phosphate levels. It is self-administered daily by injection, making it more inconvenient but more effective for long-term management of advanced disease.

Key winning strategies adopted by key players of Hypoparathyroidism Market

Focus on new product development - Leading companies like Shire, Roche, AbbVie have aggressively invested in R&D to develop new treatment options for hypoparathyroidism. In 2018, Shire launched Natpara, the first FDA approved recombinant parathyroid hormone treatment for hypoparathyroidism.

Patient support programs - Pharmaceutical companies run patient support programs to improve patient adherence and outcomes. For instance, NatparaAccess, Shire's support program, provides insurance verification, co-pay support and product delivery assistance.

Segmental Analysis of Hypoparathyroidism Market

Insights, By Treatment: Maintaining Optimal Calcium and Vitamin D Levels Drive Hormone Replacement Therapy Segment

PTH also aids renal reabsorption of calcium and encourages production of vitamin D, which enhances intestinal calcium absorption. Maintaining healthy levels of calcium and vitamin D is critical for neurological function, muscle contraction, vascular integrity and cellular signaling in patients with hypoparathyroidism. The ease of use and consistent results achieved through PTH supplementation drive its preference over other treatment options.

Insights, By Route of Administration: Oral Administration Dominates Due to Convenience

The non-invasive nature of oral drugs boosts compliance, as they do not cause pain or discomfort associated with injections. Additionally, oral drugs have lesser safety concerns and infection risks than parenteral routes. Together, the easy self-administration and risk-free profile of oral medications make them the preferred choice for hypoparathyroidism treatment.

Insights, By End User: Hospitals Lead Due to Holistic Care

Timely adjustments can be made to drug types and dosages under medical guidance. Hospitals also offer specialized services like ultrasound-guided parathyroid gland surgery. The availability of round-the-clock care during emergencies and complications drives hospitalization. Moreover, the reliance on hospitals is higher during initial diagnosis and establishment of effective medical routines for hypoparathyroidism patients.

Additional Insights of Hypoparathyroidism Market

• Prevalence: Hypoparathyroidism affects approximately 70,000 people in the United States, with surgical procedures accounting for about 75% of cases.
• Economic Burden: The high cost of lifelong treatment, including supplements and monitoring, places a significant financial burden on patients and healthcare systems.
• Regional Insights: North America dominates the hypoparathyroidism market with a 40% share, followed by Europe at 30%. The Asia-Pacific region is expected to witness the fastest growth due to increasing healthcare investments.
• Regulatory Approvals: The introduction of recombinant human parathyroid hormone (rhPTH) therapies has revolutionized treatment, providing physiological hormone replacement and reducing dependency on high-dose supplements.
• Clinical Trials: Ongoing studies are exploring gene therapies and novel delivery mechanisms, such as transdermal patches and long-acting injectables, which could significantly impact future treatment strategies.

Competitive overview of Hypoparathyroidism Market

The major players operating in the hypoparathyroidism market include Takeda Pharmaceutical Company Limited, Ascendis Pharma A/S, Amgen Inc., Entera Bio Ltd., Shire Plc, Roche Holding AG, Eli Lilly and Company, Forte Biosciences Inc., AbbVie Inc., and Novartis International AG.

Recent Developments in Hypoparathyroidism Market

Hypoparathyroidism Market Segmentation

• • By Treatment
    • Hormone Replacement Therapy
      • Recombinant Parathyroid Hormone (rhPTH)
      • Vitamin D Analogues
      • Calcium Supplements
    • Adjunctive Therapies
      • Magnesium Supplements
      • Phosphate Binders
• By Route of Administration
  • Oral
    • Tablets
    • Capsules
  • Parenteral
    • Injections
• By End User
  • Hospitals
  • Specialty Clinics
  • Homecare Settings